Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally.
Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and …

Immunization during pregnancy has been recommended in an increasing number of
countries. The aim of this strategy is to protect pregnant women and infants from severe …

A maternal vaccine to protect neonates against Group B Streptococcus invasive infection is
an unmet medical need. Such a vaccine should ideally be offered during the third trimester …

Purpose To systematically review immunogenicity and safety data of maternal group B
streptococcal (GBS) vaccines in published clinical trials until July 2023. Methods EMBASE …

Group B streptococcus (GBS) late-onset disease (LOD, occurring from 7 through 89 days of
life) is an important cause of sepsis and meningitis in infants. The pathogenesis and modes …

Abstract Background Group B Streptococcus (GBS) is the leading cause of life-threatening
infections in new-borns and may cause invasive disease, stillbirth and preterm delivery …

The development of a group B Streptococcus (GBS) vaccine for maternal immunization
constitutes a global public health priority, to prevent GBS-associated early life invasive …

Group B Streptococcus is a Gram-positive bacterium that typically colonizes 10–30% of
pregnant women, causing chorioamnionitis, preterm birth, and stillbirth, as well as neonatal …

Abstract Background Group B Streptococcus (GBS) transmission during pregnancy causes
preterm labor, stillbirths, fetal injury, or neonatal infections. Rates of adult infections are also …

Immunization of pregnant women with Group B Streptococcus (GBS) capsular
polysaccharide (CPS) conjugate vaccine (CV) could protect young infants against invasive …